Comparison · NCT01796301-sae
Teriparatide vs Romosozumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Teriparatide vs Romosozumab: serious adverse events. Trial comparisons, record NCT01796301-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01796301-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.107 | 0.0727 | 0.156 | wilson | |
| Risk in group 2 | 0.078 | 0.0493 | 0.121 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0295 | -0.0261 | 0.086 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.38 | 0.758 | 2.51 | log | |
| Odds ratio, group 1 over group 2 | 1.42 | 0.738 | 2.75 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Teriparatide than on Romosozumab | 33.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Teriparatide | Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months. | 23 | 214 | EG000 |
| Group 2 | Romosozumab | Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months. | 17 | 218 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 12 months
Source ClinicalTrials.gov
Trial
- Title
- An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
- NCT number
- NCT01796301
- Phases
- PHASE3
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Romozosumab, Teriparatide
- Lead sponsor
- Amgen
- Results first posted
- 2018-11-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01796301?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01796301-sae